Soluble Biomarkers as Predictors of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)-Insights from the Tumor Microenvironment Perspective
Open Access
- 1 October 2024
- journal article
- Published by Scifiniti Publishing in Cancer Research and Therapy Connect
- Vol. 1 (1) , 1-10
Abstract
Lung cancer is the major cause of mortality worldwide with non-small cell lung cancer (NSCLC) contributing to 85% of the cases. FDA-approved immune checkpoint inhibitors (ICI), anti-PD-1, and anti-PD-L1 are widely used as a standard treatment. However, the response rate is limited and is observed in only 20–40% of the patients. Therefore, predictive and prognostic biomarkers are needed to help differentiate responders from non-responders, enabling a better understanding of disease dynamics and facilitating more effective management through the optimal use of these valuable drugs. In this context, tissue-based biomarkers have several limitations such as invasive sampling, tumor heterogeneity and difficulty in longitudinal monitoring. Therefore, non-invasive blood-based biomarkers could serve as impactful tools as predictive and prognostic biomarkers in ICI-treated NSCLC patients. In lieu of this, this review article aims to provide updated insights on the utility of soluble molecules such as soluble immune checkpoints, exosomes and cytokines as prognostic and predictive biomarkers of response in ICI-treated NSCLC patients.Keywords
This publication has 111 references indexed in Scilit:
- Role of chemokine systems in cancer and inflammatory diseasesMedcomm, 2022
- The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyteCancer Immunology, Immunotherapy, 2021
- What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in ChinaCancer Medicine, 2019
- Identification and characterization of an alternative cancer-derived PD-L1 splice variantCancer Immunology, Immunotherapy, 2018
- A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionCancer Immunology, Immunotherapy, 2018
- Targeting Immune Checkpoints in Cancer TherapyJAMA, 2017
- CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastasesCancer Immunology, Immunotherapy, 2017
- PD-1 and cancer: molecular mechanisms and polymorphismsImmunogenetics, 2017
- The soluble isoform of CTLA‐4 as a regulator of T‐cell responsesEuropean Journal of Immunology, 2013
- Contribution of the PD‐1 ligands/PD‐1 signaling pathway to dendritic cell‐mediated CD4+ T cell activationEuropean Journal of Immunology, 2006